Samsung Biologics is seeking to acquire PolyPeptide Group in a deal valued at about 2.7 trillion won, or roughly $1.8 billion, marking a major step into the fast-growing market for GLP-1 obesity and diabetes treatments. The transaction has been described as the largest pharma-biotech acquisition ever by a South Korean company.
The move would significantly broaden Samsung Biologics' position in contract development and manufacturing, adding specialized peptide capabilities through PolyPeptide's business. That is especially important as demand rises for peptide-based medicines tied to weight loss and metabolic disease.
By pursuing PolyPeptide, Samsung Biologics appears to be strengthening both its product reach and its global manufacturing presence. The planned takeover would give the company a stronger foothold in a segment of the drug industry that has attracted intense investment as GLP-1 therapies gain worldwide attention.
The deal also highlights how major healthcare manufacturers are racing to build scale in high-demand treatment categories. For Samsung Biologics, the acquisition would not only expand its CDMO portfolio but also position it more directly within one of the most closely watched areas of the pharmaceutical market.
